Literature DB >> 24096023

Comparison of the catalytic properties of the botulinum neurotoxin subtypes A1 and A5.

Dongxia Wang1, Joan Krilich, Sabine Pellett, Jakub Baudys, William H Tepp, John R Barr, Eric A Johnson, Suzanne R Kalb.   

Abstract

Clostridium botulinum neurotoxins (BoNTs) cause the life-threatening disease botulism through the inhibition of neurotransmitter release by cleaving essential SNARE proteins. There are seven serologically distinctive types of BoNTs and many subtypes within a serotype have been identified. BoNT/A5 is a recently discovered subtype of type A botulinum neurotoxin which possesses a very high degree of sequence similarity and identity to the well-studied A1 subtype. In the present study, we examined the endopeptidase activity of these two BoNT/A subtypes and our results revealed significant differences in substrate binding and cleavage efficiency between subtype A5 and A1. Distinctive hydrolysis efficiency was observed between the two toxins during cleavage of the native substrate SNAP-25 versus a shortened peptide mimic. N-terminal truncation studies demonstrated that a key region of the SNAP-25, including the amino acid residues at 151 through 154 located in the remote binding region of the substrate, contributed to the differential catalytic properties between A1 and A5. Elevated binding affinity of the peptide substrate resulted from including these important residues and enhanced BoNT/A5's hydrolysis efficiency. In addition, mutations of these amino acid residues affect the proteolytic performance of the two toxins in different ways. This study provides a better understanding of the biological activity of these toxins, their performance characteristics in the Endopep-MS assay to detect BoNT in clinical samples and foods, and is useful for the development of peptide substrates.
© 2013. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  A; BoNT/A; Botulinum neurotoxin; D; E; G; K; LC; MS; Mass spectrometry; N-ethylmaleimide-sensitive factor; NSF; Q; R; S; SNAP-25; SNARE; V; VAMP2; alanine; arginine; aspartic acid; botulinum neurotoxin serotype A; glutamic acid; glutamine; glycine; hS; homoserine; light chain; lysine; mass spectrometry; serine; soluble NSF attachment protein 25; soluble NSF attachment receptor; valine; vesicle-associated membrane protein 2

Mesh:

Substances:

Year:  2013        PMID: 24096023      PMCID: PMC4582773          DOI: 10.1016/j.bbapap.2013.09.007

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  32 in total

1.  Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E.

Authors:  G Schiavo; O Rossetto; S Catsicas; P Polverino de Laureto; B R DasGupta; F Benfenati; C Montecucco
Journal:  J Biol Chem       Date:  1993-11-15       Impact factor: 5.157

2.  Botulinum neurotoxin C1 cleaves both syntaxin and SNAP-25 in intact and permeabilized chromaffin cells: correlation with its blockade of catecholamine release.

Authors:  P Foran; G W Lawrence; C C Shone; K A Foster; J O Dolly
Journal:  Biochemistry       Date:  1996-02-27       Impact factor: 3.162

3.  Botulinum neurotoxin types A and E require the SNARE motif in SNAP-25 for proteolysis.

Authors:  P Washbourne; R Pellizzari; G Baldini; M C Wilson; C Montecucco
Journal:  FEBS Lett       Date:  1997-11-24       Impact factor: 4.124

4.  Proteolysis of SNAP-25 by types E and A botulinal neurotoxins.

Authors:  T Binz; J Blasi; S Yamasaki; A Baumeister; E Link; T C Südhof; R Jahn; H Niemann
Journal:  J Biol Chem       Date:  1994-01-21       Impact factor: 5.157

5.  Cleavage of members of the synaptobrevin/VAMP family by types D and F botulinal neurotoxins and tetanus toxin.

Authors:  S Yamasaki; A Baumeister; T Binz; J Blasi; E Link; F Cornille; B Roques; E M Fykse; T C Südhof; R Jahn
Journal:  J Biol Chem       Date:  1994-04-29       Impact factor: 5.157

6.  Botulinum neurotoxin C1 blocks neurotransmitter release by means of cleaving HPC-1/syntaxin.

Authors:  J Blasi; E R Chapman; S Yamasaki; T Binz; H Niemann; R Jahn
Journal:  EMBO J       Date:  1993-12       Impact factor: 11.598

7.  SNARE motif and neurotoxins.

Authors:  O Rossetto; G Schiavo; C Montecucco; B Poulain; F Deloye; L Lozzi; C C Shone
Journal:  Nature       Date:  1994-12-01       Impact factor: 49.962

8.  Botulinum G neurotoxin cleaves VAMP/synaptobrevin at a single Ala-Ala peptide bond.

Authors:  G Schiavo; C Malizio; W S Trimble; P Polverino de Laureto; G Milan; H Sugiyama; E A Johnson; C Montecucco
Journal:  J Biol Chem       Date:  1994-08-12       Impact factor: 5.157

9.  Extraction and inhibition of enzymatic activity of botulinum neurotoxins/A1, /A2, and /A3 by a panel of monoclonal anti-BoNT/A antibodies.

Authors:  Suzanne R Kalb; Jianlong Lou; Consuelo Garcia-Rodriguez; Isin N Geren; Theresa J Smith; Hercules Moura; James D Marks; Leonard A Smith; James L Pirkle; John R Barr
Journal:  PLoS One       Date:  2009-04-28       Impact factor: 3.240

10.  Independent evolution of neurotoxin and flagellar genetic loci in proteolytic Clostridium botulinum.

Authors:  Andrew T Carter; Catherine J Paul; David R Mason; Susan M Twine; Mark J Alston; Susan M Logan; John W Austin; Michael W Peck
Journal:  BMC Genomics       Date:  2009-03-19       Impact factor: 3.969

View more
  16 in total

Review 1.  Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.

Authors:  Marco Pirazzini; Ornella Rossetto; Roberto Eleopra; Cesare Montecucco
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

Review 2.  Botulinum neurotoxins: genetic, structural and mechanistic insights.

Authors:  Ornella Rossetto; Marco Pirazzini; Cesare Montecucco
Journal:  Nat Rev Microbiol       Date:  2014-06-30       Impact factor: 60.633

3.  Comparative functional analysis of mice after local injection with botulinum neurotoxin A1, A2, A6, and B1 by catwalk analysis.

Authors:  Molly S Moritz; William H Tepp; Heather N'te Inzalaco; Eric A Johnson; Sabine Pellett
Journal:  Toxicon       Date:  2019-06-07       Impact factor: 3.033

4.  Holotoxin Activity of Botulinum Neurotoxin Subtype A4 Originating from a Nontoxigenic Clostridium botulinum Expression System.

Authors:  Marite Bradshaw; William H Tepp; Regina C M Whitemarsh; Sabine Pellett; Eric A Johnson
Journal:  Appl Environ Microbiol       Date:  2014-09-19       Impact factor: 4.792

5.  In vivo onset and duration of action varies for botulinum neurotoxin A subtypes 1-5.

Authors:  Sabine Pellett; William H Tepp; Regina C M Whitemarsh; Marite Bradshaw; Eric A Johnson
Journal:  Toxicon       Date:  2015-06-27       Impact factor: 3.033

Review 6.  Current status and future directions of botulinum neurotoxins for targeting pain processing.

Authors:  Sabine Pellett; Tony L Yaksh; Roshni Ramachandran
Journal:  Toxins (Basel)       Date:  2015-11-04       Impact factor: 4.546

7.  Isolation and functional characterization of the novel Clostridium botulinum neurotoxin A8 subtype.

Authors:  Skadi Kull; K Melanie Schulz; Jasmin Weisemann; Sebastian Kirchner; Tanja Schreiber; Alexander Bollenbach; P Wojtek Dabrowski; Andreas Nitsche; Suzanne R Kalb; Martin B Dorner; John R Barr; Andreas Rummel; Brigitte G Dorner
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

Review 8.  Novel Botulinum Neurotoxins: Exploring Underneath the Iceberg Tip.

Authors:  Domenico Azarnia Tehran; Marco Pirazzini
Journal:  Toxins (Basel)       Date:  2018-05-10       Impact factor: 4.546

9.  High-resolution crystal structures of the botulinum neurotoxin binding domains from subtypes A5 and A6.

Authors:  Jonathan R Davies; Amy Britton; Sai Man Liu; K Ravi Acharya
Journal:  FEBS Open Bio       Date:  2020-07-23       Impact factor: 2.693

10.  Botulinum Neurotoxin F Subtypes Cleaving the VAMP-2 Q58⁻K59 Peptide Bond Exhibit Unique Catalytic Properties and Substrate Specificities.

Authors:  Stefan Sikorra; Martin Skiba; Martin B Dorner; Jasmin Weisemann; Mirjam Weil; Sylvia Valdezate; Bazbek Davletov; Andreas Rummel; Brigitte G Dorner; Thomas Binz
Journal:  Toxins (Basel)       Date:  2018-08-01       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.